A dispensable SepIVA orthologue in Streptomyces venezuelae is associated with polar growth and not cell division.

Autor: Sen, Beer Chakra¹ (AUTHOR), Mavi, Parminder Singh¹ (AUTHOR), Irazoki, Oihane² (AUTHOR), Datta, Susmita¹ (AUTHOR), Kaiser, Sebastian¹ (AUTHOR), Cava, Felipe² (AUTHOR), Flärdh, Klas¹ (AUTHOR) klas.flardh@biol.lu.se

Publikováno v: BMC Microbiology. 11/18/2024, Vol. 24 Issue 1, p1-15. 15p.

Structural insights of an LCP protein-LytR-from Streptococcus dysgalactiae subs. dysgalactiae through biophysical and in silico methods.

Autor: Paquete-Ferreira, João^1,2, Freire, Filipe², Fernandes, Henrique S.^3,4, Muthukumaran, Jayaraman², Ramos, Joao², Bryton, Joana^1,2, Panjkovich, Alejandro⁵, Svergun, Dmitri⁵, Santos, Marino F. A.^1,2, Correia, Márcia A. S.^1,2, Fernandes, Alexandra R.^1,6, Romao, Maria Joao^1,2, Sousa, Sérgio F.^3,4, Santos-Silva, Teresa^1,2 tsss@fct.unl.pt, Kapoor, Srajan, Yadav, Dharmendra Kumar

Publikováno v: Frontiers in Chemistry. 2024, p1-16. 16p.

Implementation of Plate Imaging for Demonstration of Monoclonality in Biologics Manufacturing Development.

Autor: Zingaro K; Alexion Pharmaceuticals, Inc., New Haven, CT, USA; kyle.zingaro@gmail.com david.shaw@gene.com., Shaw D; Genentech, Inc., South San Francisco, CA, USA; kyle.zingaro@gmail.com david.shaw@gene.com., Carson J; AbbVie Bioresearch Center, Worcester, MA, USA., Mayer-Bartschmid A; Bayer AG, Pharmaceuticals, Research and Development, Cell and Protein Sciences, Wuppertal, Germany., Bender C; Bayer AG, Pharmaceuticals, Research and Development, Cell and Protein Sciences, Wuppertal, Germany., Alves C; Biogen, Cell Culture Development, Cambridge, MA, USA., Mcvey D; Bristol-Myers Squibb, Pennington, NJ, USA., Qian NX; Bristol-Myers Squibb, Devens, MA, USA., Wei Q; Celgene Corporation, Summit West, Summit, NJ, USA., Laird MW; Genentech, Inc., South San Francisco, CA, USA., Zhu Y; GSK, King of Prussia, PA, USA., Emmins R; GSK, Stevenage, UK., Follit JA; ImmunoGen, Inc., Waltham, USA., Porter A; Lonza Biologics plc, Slough, UK., Racher AJ; Lonza Biologics plc, Slough, UK., Milne S; Lonza Biologics plc, Slough, UK., Carubelli I; Lonza Biologics plc, Slough, UK., Du Z; Merck & Co., Inc., Kenilworth, NJ, USA., Khatri A; Merck & Co., Inc., Kenilworth, NJ, USA., Failly M; Merck Biodevelopment, Martillac, France., Broly H; Merck Serono S.A., Fenil-sur-Corsier, Switzerland., Lee F; Morphotek, Inc., Exton, PA, USA., Reeser M; Morphotek, Inc., Exton, PA, USA., Spidel J; Morphotek, Inc., Exton, PA, USA., Anderson K; Pfizer BioTherapeutics Pharmaceutical Sciences, Andover, MA, USA., Demaria C; Sanofi Biopharmaceutics Development, Framingham, MA USA., Di-Carlo J; Sanofi Biopharmaceutics Development, Vitry-sur-Seine, France., Gill J; Shire, Lexington, MA, USA., Lundquist A; Shire, Lexington, MA, USA., Kumar SR; Takeda Pharmaceuticals International Co., Cambridge, MA, USA; and., Gill T; BioPhorum Development Group, Sheffield, UK.

Publikováno v: PDA journal of pharmaceutical science and technology [PDA J Pharm Sci Technol] 2018 Jul-Aug; Vol. 72 (4), pp. 438-450. Date of Electronic Publication: 2018 Apr 18.

Specificity of human anti-variable heavy (VH) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor-α receptor 1.

Autor: Cordy, J. C., Morley, P. J., Wright, T. J., Birchler, M. A., Lewis, A. P., Emmins, R., Chen, Y. Z., Powley, W. M., Bareille, P. J., Wilson, R., Tonkyn, J., Bayliffe, A. I., Lazaar, A. L.

Publikováno v: Clinical & Experimental Immunology; Nov2015, Vol. 182 Issue 2, p139-148, 10p, 2 Diagrams, 4 Charts, 3 Graphs

The C‐terminal domain of MinC, a cell division regulation protein, is sufficient to form a copolymer with MinD.

Autor: Wang, Na¹ (AUTHOR), Sun, Haiyu¹ (AUTHOR), Zhao, Kairui² (AUTHOR), Shi, Runqing¹ (AUTHOR), Wang, Shenping¹ (AUTHOR), Zhou, Yao¹ (AUTHOR), Zhai, Meiting² (AUTHOR), Huang, Chenghao¹ (AUTHOR), Chen, Yaodong^1,2 (AUTHOR) ydchen@nwu.edu.cn

Publikováno v: FEBS Journal. Oct2023, Vol. 290 Issue 20, p4921-4932. 12p.